ABSTRACT PURPOSE: Anticoagulant drugs are among the most common medications that cause adverse drug events (ADEs) in hospitalized patients. We performed a 5-year retrospective study at Brigham and Women's Hospital to determine clinical characteristics, types, root causes, and outcomes of anticoagulant-associated ADEs.
hospitalized patients. 1, 4, 6, 11, 14 Despite implementation of computerized provider order entry, electronic medication administration records, and improved infusion pump technology ("smart pumps"), medication errors involving anticoagulant medications remain common. 11, 12 Elderly 15, 16 and cardiac patients 14 represent populations at particularly high risk for suffering anticoagulantassociated ADRs.
To determine the clinical characteristics, types, severity, root causes, and outcomes of anticoagulant-associated ADEs, we performed a 5-year retrospective study of the Safety Reporting System at Brigham and Women's Hospital. We reviewed discrete ADEs that originated during hospitalization at Brigham and Women's Hospital. We also conducted an analysis of the cost associated with hospitalizations in which ADRs occurred.
METHODS

Patient Population
Brigham and Women's Hospital is a 793-bed acute tertiary care facility providing medical and surgical care for patients with general medical, cardiothoracic, orthopedic, oncologic, neurologic, obstetric and gynecologic, neonatal, urologic, and gastrointestinal conditions. Brigham and Women's Hospital utilizes a Medical Informatics System that integrates an online medical record, computerized provider order entry, an electronic medication administration record, and an electronic safety reporting system. The Safety Reporting System is a voluntary computerized reporting system for ADRs and medication errors, which was instituted in May 2004.
Data Collection
We reviewed all inpatient anticoagulant-associated ADEs, including ADRs and medication errors, reported at Brigham and Women's Hospital through the Safety Reporting System from May 2004 to May 2009. Inpatient events for the purpose of our study were required to have originated during hospitalization at Brigham and Women's Hospital. We excluded reported anticoagulant-associated ADEs that took place in the Emergency Department, Operating Room, Cardiac Catheterization Laboratory, Cardiovascular Recovery Room, Post-Anesthesia Care Unit, and Neonatal Intensive Care Unit because medication administration records were not consistently computerized in these units during the registry period. We defined an ADR as a response to a drug normally used for prophylaxis or therapy of disease and that was noxious and unintended. 17 A medication error was defined as an event that caused or led to inappropriate medication use or patient harm. 17 A medication error that was discovered and corrected before reaching the patient was classified as a near miss. All isolated medication errors and ADRs that resulted from medication errors were considered potentially preventable.
We searched the Safety Reporting System using Risk Monitor Pro (rL Solutions, Inc., Cambridge, Mass). We evaluated the patient characteristics, ADE type and severity, root cause, and outcomes of all anticoagulation-associated medication errors and ADRs. All patient records were reviewed for evidence of treatment with an anticoagulant medication. Hemorrhagic events were classified according to the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) criteria for severe or life-threatening, moderate, or mild bleeding. 18 We obtained 30-day follow-up for 100% of patients included in the registry.
We included all anticoagulant medications administered for prophylaxis and treatment of thromboembolic events. ADEs associated with the use of the following anticoagulants were reviewed: unfractionated heparin, low-molecular-weight heparin, fondaparinux, warfarin, and direct thrombin inhibitors, such as argatroban, bivalirudin, and lepirudin. A multidisciplinary team, including physicians, pharmacists, and a hospital patient safety officer, reviewed all reported anticoagulant-related events and evaluated the root case of all ADEs.
We also collected data about the cost associated with hospitalizations in which ADEs occurred. Because medication errors that do not culminate in an ADR do not add significant incremental cost to hospitalization, we included only ADRs in our cost analysis. ADRs that added significant incremental cost to hospitalization were distinguished from those that did not by consensus of a physician (GP), pharmacist (TNN), and patient safety officer (KF). While patients may have suffered multiple ADRs during a hospital admission, we analyzed costs incurred after the initial event. We utilized a software program for cost accounting that is capable of tabulating the cost associated with a patient admission (Transitions System Incorporated, Waltham, Mass). We sorted costs by the following categories: nursing, pharmacy, blood products, clinical laboratory, radiology, surgery, nonsurgical intervention, and anesthesia. We compared total and
CLINICAL SIGNIFICANCE
• Most anticoagulant-associated adverse drug events (70%) are potentially preventable.
• Transcription errors comprise the most frequent root cause of anticoagulantassociated medication errors, and medication errors are a common root cause of anticoagulant-associated adverse drug reactions.
• After anticoagulant-associated adverse drug reactions, most hospitalization expenditures are attributable to nursing and pharmacy costs.
• Efforts to minimize anticoagulant-associated medication errors are warranted to improve patient safety and decrease hospitalization costs.
component costs of hospitalization for admissions in which an ADR occurred and added incremental expense with those for admissions in which an ADR occurred but was not determined to incur incremental cost.
Statistical Methods
Descriptive statistics including baseline characteristics; variables related to ADEs and those pertaining to outcomes were stratified as continuous or binary. Continuous variables were presented as medians with interquartile ranges. Binary variables were presented as numbers and proportions. Cost variables were presented as means with standard deviations and were compared using a 2-sample t-test. All reported P-values were 2-sided, and a P-value of Ͻ.05 was considered statistically significant. All statistical analyses were performed using STATA version 9.2 (STATA Corp., College Station, Tex).
RESULTS
Baseline Characteristics
Patients who suffered anticoagulant-associated ADEs had a median age of 62 years (Table 1) . Their median body mass index was 27.4 kg/m 2 . Patients who suffered anticoagulantassociated ADEs had a median length of stay of 13 days. Patients with anticoagulant-associated ADEs had a high frequency of medical conditions, such as atrial fibrillation, history of deep vein thrombosis or pulmonary embolism, heart failure, ischemic heart disease, chronic kidney disease, and stroke, that increase the risk of thromboembolism.
Characteristics of Anticoagulant-associated Adverse Drug Events
In 250,725 admissions over the 5-year study period, there were 463 anticoagulant-associated ADEs reported. Of these anticoagulant-associated ADEs, 226 were medication errors (48.8%), 141 were ADRs (30.5%), and 96 (20.7%) involved both a medication error and ADR. Seventy percent of anticoagulant-associated ADEs were potentially preventable ( Table 2) . Unfractionated heparin (58%) and warfarin (21%) were the most commonly implicated drugs in anticoagulant-associated ADEs. An average of 1.4 anticoagulant-associated ADEs occurred per patient over the 5-year study period.
Characteristics of Anticoagulant-associated Medication Errors
The most frequent type of anticoagulant-associated medication errors were missed medication doses (25%) and wrong rate or frequency (23%) ( Table 3) . Transcription errors (48%) were the most frequent root cause of anticoagulantassociated medication errors, followed by memory lapses (16%).
Characteristics of Anticoagulant-associated Adverse Drug Reactions
The most frequent anticoagulant-associated ADRs were abnormal coagulation studies (72%), any bleeding (25%), and thrombocytopenia (18%) ( Table 4) . Seventy-two percent of all ADRs were associated with at least one occurrence of excessive anticoagulation, such as a super-therapeutic international normalized ratio or activated partial thromboplastin time. Seventeen percent of anticoagulant-associated ADRs culminated in transfusion of at least one unit of packed red blood cells. Undetected predisposing conditions (58%), such as a previously unknown drug allergy, and medication errors (40%) comprised the most common root causes of anticoagulant-associated ADRs.
Outcomes of Anticoagulant-associated Adverse Drug Events
Death within 30 days of anticoagulant-associated ADEs occurred in 11% of patients. In-hospital death occurred after 5.6% of anticoagulant-associated ADEs, while death after discharge but within 30 days of the ADE was observed in 5% (Table 5) . A rehabilitation center stay was frequently required (40%) after an admission in which an anticoagulant-associated ADE occurred. Patients who suffered anticoagulant-associated ADEs had a high rate of re-hospitalization within 30 days of the ADE (17.5%).
Cost Analysis of Anticoagulant-associated Adverse Drug Reactions
Most hospitalization expenditures after an anticoagulantassociated ADR were attributable to nursing costs (mean $33,189 per ADR) followed by pharmacy costs (mean $7451 per ADR) ( Table 6 ). ADRs that were determined to add incremental expense were associated with significant increases in total hospitalization cost (mean $118,429 vs $54,858, P ϭ .02) as well as cost after the ADR (mean $89,733 vs $23,680, P ϭ .004) compared with ADRs in which no incremental cost was determined to be incurred ( Table 7 ). ADRs that were determined to add incremental cost to hospitalization were associated with significant increases in costs of nursing, pharmacy, blood products, clinical laboratory, and radiology.
DISCUSSION
We found that 48.8% of anticoagulant-associated ADEs were medication errors, 30.5% were ADRs, and 20.7% involved both medication errors and ADRs. Seventy percent of all reported anticoagulant-associated ADEs were potentially preventable. Transcription errors were the most common root cause of medication errors, while undetected predisposing conditions and medication errors were the most frequent root causes of ADRs. We noted high 30-day mortality (11%) in patients who experienced an anticoagulantassociated ADE during hospitalization. We observed high post-ADE hospitalization costs, largely attributable to nursing and pharmacy expenditures.
We had implemented computerized provider order entry, an electronic medication administration record, "smart" infusion pumps, and barcode technology before the registry was instituted. Therefore, we were surprised to observe that 70% of anticoagulant-associated ADEs were potentially preventable and that 40% of related ADRs were due to medication errors. Our data corroborate previous reports demonstrating that a substantial proportion of ADEs are due to medication errors and therefore potentially preventable. 4, 5 Computerized provider order entry, 5 improved infusion pump technology, 11 and implementing barcode technology 8, 9 reduce medication errors. However, our root cause analysis suggests that further improvements can be made to reduce anticoagulant-associated medication errors, particularly those due to transcription errors. While computerized provider order entry, "smart" infusion pump technology, electronic medication administration records, and barcode technology reduce the frequency of some transcription errors, human error may occur at transition points among these clinical tools and result in mistakes at any number of steps in medication transcription. The emergence of novel oral anticoagulants that are administered in fixed doses may further reduce dosing and infusion pump errors. 19 We observed high 30-day mortality (11%) in patients suffering an anticoagulant-associated ADE during hospitalization. We speculate that this may be related to a combination of high medical acuity of patients suffering anticoagulant-associated ADEs and complications of the ADEs themselves. Patients with anticoagulant-associated ADEs had a high frequency of medical conditions such as heart failure, ischemic heart disease, chronic kidney disease, and stroke, all of which may increase patient vulnerability to the complications of anticoagulant-associated ADEs. Furthermore, anticoagulant-associated ADEs may be a marker for fragile patients with complicated hospital courses and long lengths of stay. The contribution of medical errors, including those associated with ADEs, to deaths occurring during hospitalization, may be overestimated in studies relying on physician review. 20 Regardless of whether anticoagulantassociated ADEs contribute to increased mortality or are †Costs are rounded to the nearest US dollar. markers for higher medical acuity, patients who suffer these events represent a particularly vulnerable population. Accordingly, Quality Improvement initiatives to reduce anticoagulant-associated ADEs are critical. Most hospitalization costs after an anticoagulant-associated ADE were attributable to nursing and pharmacy expenses. ADRs that incurred incremental cost doubled the total hospitalization costs and nearly quadrupled postevent costs compared with ADRs that did not incur any incremental expense. Our findings are similar to other reports that demonstrate the heavy financial burden of ADEs. 13, 21, 22 Based on these data, efforts to reduce anticoagulant-associated ADEs have the potential to reduce hospitalization costs as well as improve patient safety.
Our data were obtained from a voluntary patient safety reporting system and therefore might be limited by underreporting and selective reporting, in which only the most severe ADEs or those with the greatest consequences are reported. Because we excluded patient care areas in which medication administration records were not consistently computerized, we may have omitted subgroups of patients who had suffered a higher proportion of anticoagulant-associated ADEs. Because anticoagulant medications are given throughout the hospital but not all patient care areas have electronic medication administration records, it is not possible to calculate the denominator of patients exposed to anticoagulants. Therefore, we could not calculate the incidence of anticoagulantassociated ADEs and could not identify an appropriate comparison population of patients exposed to anticoagulant drugs who did not suffer ADEs. In addition, our analysis did not encompass community-acquired ADEs that resulted in hospitalization. While 5 deaths were clearly attributable to ADE-related bleeding (n ϭ 1) or thromboembolism (n ϭ 4), we were not able to quantify the contribution of ADEs to other deaths in this cohort. Finally, because of limitations in our cost accounting software, we were unable to separate costs incurred after the initial ADR from costs associated with subsequent events in a particular patient during the same hospitalization.
The methodology utilized in this analysis is consistent with published criteria for evaluating the scientific value of clinical data registries. 23 We utilized a large database generated from a tertiary care center that is representative of similar acute care facilities. Our study provides real-world insights into anticoagulant-associated ADEs from a medical center that has implemented an electronic health record that †Costs are rounded to the nearest US dollar.
integrates computerized provider order entry, an electronic medication administration record, "smart" infusion pumps, and barcode technology. We utilized a multidisciplinary group of physicians, pharmacists, and a patient safety officer to provide the highest accuracy for classifying events and determining root causes of ADEs. Finally, we provided outcomes data for patients who suffered anticoagulantassociated ADEs with 100% follow-up.
CONCLUSIONS
Most anticoagulant-associated ADEs among inpatients result from medication errors and are therefore potentially preventable. Transcription errors are the most common cause of medication errors which, in turn, are a frequent cause of anticoagulant-associated ADRs. We observed elevated 30-day mortality among patients who suffered an anticoagulant-associated ADE and high hospitalization costs following ADRs. Further efforts to reduce anticoagulant-associated medication errors are warranted to improve patient safety and decrease health care expenditures.
